Article
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Gastroenterology - 1 Oct 2015
Lawitz Eric, Makara Mihály, Akarca Ulus Salih, Thuluvath Paul J, Preotescu Liliana Lucia, Varunok Peter, Morillas Rosa Ma, Hall Coleen, Mobashery Niloufar, Redman Rebecca, Pilot-Matias Tami, Vilchez Regis A, Hézode Christophe
Abstract excerpt
BACKGROUND & AIMS: Interferon-free treatment options are rapidly evolving for patients with chronic hepatitis C virus (HCV) genotype 1b (GT1b) infection with cirrhosis and for nonresponders to prior pegylated interferon and ribavirin therapy. We performed a phase 2b, open-label trial of the combination of ombitasvir (a NS5A replication complex inhibitor), paritaprevir, and ritonavir (an NS3/4A protease...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.